Published 2014 | Version v1
Book

Radiation-induced normal tissue damage: implications for radiotherapy

  • 1. Radiation Research Program, National Cancer Institute, Bethesda, MD 20892-9727 (United States)

Description

Radiotherapy is an important treatment modality for many malignancies, either alone or as a part of combined modality treatment. However, despite technological advances in physical treatment delivery, patients suffer adverse effects from radiation therapy due to normal tissue damage. These side effects may be acute, occurring during or within weeks after therapy, or intermediate to late, occurring months to years after therapy. Minimizing normal tissue damage from radiotherapy will allow enhancement of tumor killing and improve tumor control and patients quality of life. Understanding mechanisms through which radiation toxicity develops in normal tissue will facilitate the development of next generation radiation effect modulators. Translation of these agents to the clinic will also require an understanding of the impact of these protectors and mitigators on tumor radiation response. In addition, normal tissues vary in radiobiologically important ways, including organ sensitivity to radiation, cellular turnover rate, and differences in mechanisms of injury manifestation and damage response. Therefore, successful development of radiation modulators may require multiple approaches to address organ/site-specific needs. These may include treatments that modify cellular damage and death processes, inflammation, alteration of normal flora, wound healing, tissue regeneration and others, specifically to counter cancer site-specific adverse effects. Further, an understanding of mechanisms of normal tissue damage will allow development of predictive biomarkers; however harmonization of such assays is critical. This is a necessary step towards patient-specific treatment customization. Examples of important adverse effects of radiotherapy either alone or in conjunction with chemotherapy, and important limitations in the current approaches of using radioprotectors for improving therapeutic outcome will be highlighted. (author)

Part of:
Proceedings of the international conference on radiation biology: frontiers in radiobiology - immunomodulation, countermeasures and therapeutics: abstract book, souvenir and scientific programme

Additional details

Publishing Information

Publisher
Institute of Nuclear Medicine and Allied Sciences
Imprint Place
Delhi (India)
Imprint Title
Proceedings of the international conference on radiation biology: frontiers in radiobiology - immunomodulation, countermeasures and therapeutics: abstract book, souvenir and scientific programme
Imprint Pagination
314 p.
Journal Page Range
p. 33

Conference

Title
international conference on radiation biology: frontiers in radiobiology - immunomodulation, countermeasures and therapeutics
Acronym
ICRB-2014
Dates
11-13 Nov 2014
Place
New Delhi (India)

INIS

Country of Publication
India
Country of Input or Organization
India
INIS RN
46095440
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Resource subtype / Literary indicator
Conference
Descriptors DEI
DNA DAMAGES; NEOPLASMS; RADIATION DOSES; RADIOPROTECTIVE SUBSTANCES; RADIOTHERAPY
Descriptors DEC
DISEASES; DOSES; DRUGS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; RESPONSE MODIFYING FACTORS; THERAPY

Optional Information